Direct control of CAR T cells through small molecule-regulated antibodies
Many next-generation antibody therapeutics have enhanced potency but the risk of adverse events. Here the authors develop a conditionally activated, single-module CAR.
Saved in:
Main Authors: | Spencer Park, Edward Pascua, Kevin C. Lindquist, Christopher Kimberlin, Xiaodi Deng, Yvonne S. L. Mak, Zea Melton, Theodore O. Johnson, Regina Lin, Bijan Boldajipour, Robert T. Abraham, Jaume Pons, Barbra Johnson Sasu, Thomas J. Van Blarcom, Javier Chaparro-Riggers |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/a6c74f8c5d424b06a2dbc5aa3382a4ec |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
by: Shahram Salek-Ardakani, et al.
Published: (2021) -
Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire
by: Yik Andy Yeung, et al.
Published: (2016) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
by: Sergey Kulemzin, et al.
Published: (2021) - Car and driver
-
CAR T-CELL
by: Francesco Saglio
Published: (2021)